<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02319564</url>
  </required_header>
  <id_info>
    <org_study_id>ConRCT1</org_study_id>
    <nct_id>NCT02319564</nct_id>
  </id_info>
  <brief_title>Combined Glucocorticoid Adrenergic Therapy For Wheezy Preschool Children</brief_title>
  <acronym>CONjuGATE</acronym>
  <official_title>Randomized Trial Assessing the Effectiveness of Beclomethasone and Combination Beclomethasone and Salbutamol as Compared With Placebo in Preschool Aged Children With Wheeze</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Eastern Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators goal is to conduct a pilot randomized controlled trial (RCT) whose purpose
      is to determine the feasibility of a randomized trial designed to determine if either inhaled
      beclomethasone or a combination of inhaled beclomethasone/salbutamol (Clenil Compositum) are
      superior to placebo in treating pre-school aged children with an acute wheezing episode.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study population too narrow - unable to recruit any patients.
  </why_stopped>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduce unplanned-symptomatic visits to clinicians</measure>
    <time_frame>After enrolment is complete</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduce the number of days with respiratory symptoms</measure>
    <time_frame>Will be analyzed 1-2 months after enrolment is complete, looking at the full follow-up period of 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduce the need for rescue salbutamol use</measure>
    <time_frame>Will be analyzed 1-2 months after enrolment is complete, looking at the full follow-up period of 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduce hospitalization rates of target population</measure>
    <time_frame>Will be analyzed 1-2 months after enrolment is complete, looking at the full follow-up period of 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduce overall societal health care costs of target population</measure>
    <time_frame>Will be analyzed 1-2 months after enrolment is complete, looking at the full follow-up period of 21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Wheeze</condition>
  <arm_group>
    <arm_group_label>beclomethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>beclomethasone dipropionate 250mcg per puff per puff (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max速, Plattsburgh, NY, USA). One puff BID for 14 days.
Non-identifiable MDI prepared by Chiesi Farmaceutici Inc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>beclomethasone and salbutamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>beclomethasone diprionate 250mcg and salbutamol 100mcg per puff (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max速, Plattsburgh, NY, USA). One puff BID for 14 days.
Non-identifiable MDI prepared by Chiesi Farmaceutici Inc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max速, Plattsburgh, NY, USA). One puff BID for 14 days.
Non-identifiable MDI prepared by Chiesi Farmaceutici Inc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclomethasone</intervention_name>
    <arm_group_label>beclomethasone</arm_group_label>
    <other_name>Clenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclomethasone and Salbutamol</intervention_name>
    <arm_group_label>beclomethasone and salbutamol</arm_group_label>
    <other_name>Clenil Compositum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aerochamber Max速</intervention_name>
    <arm_group_label>beclomethasone</arm_group_label>
    <arm_group_label>beclomethasone and salbutamol</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Masked Spacer for metered dose inhaler</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. children 12-60 months of age

          2. wheeze on auscultation

          3. mild respiratory distress as measured by a score of &lt; 3 on the Pediatric Respiratory
             Assessment Measure (PRAM)

          4. discharged home after evaluation by their ED physician.

        Exclusion Criteria:

          1. treatment with oral or parenteral corticosteroids in the last 14 days

          2. treatment with more than 2 doses of inhaled corticosteroids in the previous seven days

          3. presence of a severe co-morbidity such as bronchopulmonary dysplasia, cystic fibrosis,
             congenital heart disease, adrenal disorder or immune deficiency

          4. previously enrolled into this study or concurrently enrolled in another intervention
             trial

          5. lack of telephone access or presence of a significant language barrier
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>60 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2014</study_first_submitted>
  <study_first_submitted_qc>December 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2014</study_first_posted>
  <last_update_submitted>November 11, 2016</last_update_submitted>
  <last_update_submitted_qc>November 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>David W Johnson</investigator_full_name>
    <investigator_title>Professor, Departments of Pediatrics, Pharmacology &amp; Physiology</investigator_title>
  </responsible_party>
  <keyword>Wheeze</keyword>
  <keyword>Asthma</keyword>
  <keyword>Randomized Trial</keyword>
  <keyword>Pre-school aged children</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

